Abstract
This study aimed to evaluate the efficacy and safety of fecal microbiota transplantation (FMT) as an adjunctive therapy for depressive episodes. This study recruited 46 participants aged 18–65 from January 2022 to December 2023 who were diagnosed with depression according to the International Classification of Diseases, 10th edition. They were randomly divided into two groups to receive different treatments, including FMT combined with medication group (test group, n = 23) and the medication-only group (control group, n = 23). Assessments were performed before and two weeks after treatment. Ten predominant gut microbiota species were analyzed, and the Hamilton’s Depression Scale-24(HAMD-24) was used to evaluate depressive symptoms. Adverse events related to treatment were assessed using an adverse event scale and laboratory tests. The main evaluation indicators included the reduction rate of HAMD-24 scores, treatment efficacy rate, and changes in the indicators of the ten predominant intestinal bacteria before and after transplantation. Safety assessment indicators included adverse events, blood routine, biochemistry, electrocardiogram, immunological parameters (immunoglobulins and complement), hypersensitive C-reactive protein(hs-CRP), thyroid function, and glycated hemoglobin. The rank-sum test was performed to compare differences in microbiota before and after FMT treatment. The relationship between gut microbiota and depression severity was examined by means of correlation analysis. The baseline HAMD-24 scores showed no significant difference between the test and control groups (P > 0.05). After two weeks treatment, the reduction in HAMD-24 scores (P = 0.048) and the HAMD-24 reduction rate (P = 0.016) were significantly higher in the test group than control group (P < 0.05). Following FMT treatment, Enterococcus, Lactobacillus, Bifidobacterium, and Butyricicoccus levels significantly increased compared to baseline (P < 0.05). Linear discriminant analysis(LDA) revealed a significant post-treatment increase in Enterococcus relative abundance (P = 0.02). In the test group, baseline-enriched Clostridium prausnitzii (P = 0.040), Butyricicoccus (P = 0.029), and Eubacterium rectale (P = 0.004) showed significant negative correlations with HAMD-24 scores, whereas post-treatment Enterococcus was correlated with HAMD-24 scores (P = 0.030). Adverse event incidence was 28.6% in the test group and 30% in the control group, with no significant difference (P = 0.928). Reported discomforts during FMT treatment—nausea, vomiting, and nasopharyngeal discomfort—were mild and self-resolving, with no serious adverse events observed. The administration of FMT as an adjunctive therapy demonstrates superior improvement in depressive symptoms and is deemed safe with no apparent adverse reactions. There was no change in the composition of gut microbiota structure before and after FMT in patients with depression. Enterococcus showed a significant relative abundance increase in the gut after FMT. The post-treatment Enterococcus was correlated with HAMD-24 scores.
Data availability
Data is provided within the manuscript or supplementary information files.
References
COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 398, 1700–1712 (2021).
World Health Organization. World Mental Health Report: Transforming Mental Health for All (WHO, 2022).
GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 9, 137–150 (2022).
Schildkraut, J. J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry. 122, 509–522 (1965).
Coppen, A. The biochemistry of affective disorders. Br. J. Psychiatry. 113, 1237–1264 (1967).
Rush, A. J. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry. 163, 1905–1917 (2006).
Cipriani, A. et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391, 1357–1366 (2018).
Krishnan, V. & Nestler, E. J. The molecular neurobiology of depression. Nature 455, 894–902 (2008).
Bercik, P. The microbiota-gut-brain axis: learning from intestinal bacteria? Gut 60, 288–289 (2011).
Carabotti, M., Scirocco, A., Maselli, M. A. & Severi, C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Annals Gastroenterol. 28, 203–209 (2015).
Socała, K. et al. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Pharmacol. Res. 172, 105840 (2021).
Zheng, P. et al. Gut microbial signatures can discriminate unipolar from bipolar depression. Adv. Sci. (Weinh). 7, 1902862 (2020).
Valles-Colomer, M. et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat. Microbiol. 4, 623–632 (2019).
Ghosh, S., Whitley, C. S., Haribabu, B. & Jala, V. R. Regulation of intestinal barrier function by microbial metabolites. Cell. Mol. Gastroenterol. Hepatol. 11, 1463–1482 (2021).
Li, N. et al. Fecal microbiota transplantation from chronic unpredictable mild stress mice donors affects anxiety-like and depression-like behavior in recipient mice via the gut microbiota-inflammation-brain axis. Stress 22, 592–602 (2019).
Liu, S. et al. Gut microbiota regulates depression-like behavior in rats through the neuroendocrine-immune-mitochondrial pathway. Neuropsychiatr Dis. Treat. 16, 859–869 (2020).
Slyepchenko, A. et al. Gut microbiota, bacterial translocation, and interactions with diet: pathophysiological links between major depressive disorder and non-communicable medical comorbidities. Psychother. Psychosom. 86, 31–46 (2017).
Caspani, G., Kennedy, S., Foster, J. A. & Swann, J. Gut microbial metabolites in depression: understanding the biochemical mechanisms. Microb. Cell. 6, 454–481 (2019).
Młynarska, E. et al. The role of the microbiome-brain-gut axis in the pathogenesis of depressive disorder. Nutrients 14, 1921 (2022).
Sun, W., Zhang, J. & Mao, Q. Advances in clinical practice of fecal microbiota transplantation. Chin. J. Microecol.. 29, 1197–1203 (2017).
Surawicz, C. M. et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 108, 478–499 (2013).
Debast, S. B., Bauer, M. P., Kuijper, E. J. & European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. 20 (Suppl 2), 1–26 (2014).
Sinyor, M., Schaffer, A. & Levitt, A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can. J. Psychiatry. 55, 126–135 (2010).
Trivedi, M. H. et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry. 163, 28–40 (2006).
Rush, A. J. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry. 163, 1905–1917 (2006).
Cipriani, A. et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Focus (Am Psychiatr Publ. 16, 420–429 (2018).
Tian, Y. Y. & Jia, X. F. Advantages and pathogenicity of Enterococci. Lab. Med. 38, 1101–1105 (2023).
Wang, Y. et al. Effects of combined live bifidobacterium, lactobacillus enterococcus and bacillus cereus tablets on post-stroke depression and serum inflammatory factorse. Discov. Med. 35, 312–320 (2023).
Jang, H. M. et al. Enterococcus faecium and Pediococcus acidilactici deteriorate Enterobacteriaceae-induced depression and colitis in mice. Sci. Rep. 12, 9389 (2022).
Knuesel, T. & Mohajeri, M. H. The role of the gut microbiota in the development and progression of major depressive and bipolar disorde r. Nutrients 14, 37 (2021).
Fisher, K. & Phillips, C. The ecology, epidemiology and virulence of Enterococcus. Microbiol. Read. 155, 1749–1757 (2009).
Mohamed, J. A. & Huang, D. B. Biofilm formation by enterococci. J. Med. Microbiol. 56, 1581–1588 (2007).
Steck, N. et al. Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology 141, 959–971 (2011).
Bäumler, A. J. & Sperandio, V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 535, 85–93 (2016).
Vancamelbeke, M. & Vermeire, S. The intestinal barrier: a fundamental role in health and disease. Expert Rev. Gastroenterol. Hepatol. 11, 821–834 (2017).
Moylan, S., Maes, M., Wray, N. R. & Berk, M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol. Psychiatry 18, 595–606 (2013).
Miller, A. H. & Raison, C. L. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 16, 22–34 (2016).
D’Mello, C. et al. Probiotics improve inflammation-associated sickness behavior by altering communication between the peripheral immune system and the brain. J. Neurosci. 35, 10821–10830 (2015).
Bruce-Keller, A. J. et al. Obese-type gut microbiota induce neurobehavioral changes in the absence of obesity. Biol. Psychiatry. 77, 607–615 (2015).
Martín, R. et al. Faecalibacterium: a bacterial genus with promising human health applications. FEMS Microbiol. Rev. 47, 039 (2023).
Zhang, W. et al. Clostridium butyricum RH2 alleviates chronic foot shock stress-induced behavioral deficits in rats via PAI-1. Front. Pharmacol. 13, 845221 (2022).
Hu, X. et al. Changes of gut microbiota reflect the severity of major depressive disorder: a cross sectional study. Transl. Psychiatry 13, 137 (2023).
Liu, L. et al. Gut microbiota and its metabolites in depression: from pathogenesis to treatment. EBioMedicine 90, 104527 (2023).
Xiao, W. et al. The microbiota-gut-brain axis participates in chronic cerebral hypoperfusion by disrupting the metabolism of short-chain fatty acids. Microbiome 10, 62 (2022).
van de Wouw M., et al. Short-chain fatty acids: microbial metabolites that alleviate stress-induced brain-gut axisalterations. J. Physiol. 96, 4923-4944 (2018)
Xu Z., et al. Fecal microbiota transplantation from healthy donors reduced alcohol-induced anxiety anddepression in an animal model of chronic alcohol exposure. Chin J. Physiol. 61, 360–371 (2018)
Cai, T., Shi, X., Yuan, L. Z., Tang, D. & Wang, F. Fecal microbiota transplantation in an elderly patient with mental depression. Int. Psychogeriatr. 31, 1525–1526 (2019).
Chinna Meyyappan, A., Forth, E., Wallace, C. J. K. & Milev, R. Effect of fecal microbiota transplant on symptoms of psychiatric disorders: a systematic review. BMC Psychiatry. 20, 299 (2020).
Cooke, N. C. A. et al. The safety and efficacy of fecal microbiota transplantation in a population with bipolar disorder during depressive episodes: study protocol for a pilot randomized controlled trial. Pilot Feasibility Stud. 7, 142 (2021).
Evrensel, A. & Tarhan, K. N. Emerging role of Gut-microbiota-brain axis in depression and therapeutic implication. Prog Neuropsychopharmacol. Biol. Psychiatry. 106, 110138 (2021).
Hinton, R. A case report looking at the effects of faecal microbiota transplantation in a patient with bipolar disorder. Aust. N. Z. J. Psychiatry. 54, 649–650 (2020).
Dinan, T. G., Stanton, C. & Cryan, J. F. Psychobiotics: a novel class of psychotropic. Biol. Psychiatry. 74, 720–726 (2013).
Wallace, C. J. K. & Milev, R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann. Gen. Psychiatry. 16, 14 (2017).
Huang, R., Wang, K. & Hu, J. Effect of probiotics on depression: a systematic review and meta-analysis of randomized controlled trials. Nutrients 8, 483 (2016).
Wang, H., Lee, I. S., Braun, C. & Enck, P. Effect of probiotics on central nervous system functions in animals and humans: a systematic review. J. Neurogastroenterol. Motil. 22, 589–605 (2016).
Sudo, N. et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J. Physiol. 558, 263–275 (2004).
Akkasheh, G. et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Nutrition 32, 315–320 (2016).
Romijn, A. R., Rucklidge, J. J., Kuijer, R. G. & Frampton, C. A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression. Aust. N Z. J. Psychiatry. 51, 810–821 (2017).
Tillmann, S., Abildgaard, A., Winther, G. & Wegener, G. Altered fecal microbiota composition in the Flinders sensitive line rat model of depression. Psychopharmacol. (Berl). 236, 1445–1457 (2019).
Chen, J. J. et al. Sex differences in gut microbiota in patients with major depressive disorder. Neuropsychiatr. Dis. Treat. 14, 647–655 (2018).
Rao, J. et al. Fecal microbiota transplantation ameliorates stress-induced depression-like behaviors associated with the inhibition of glial and NLRP3 inflammasome in rat brain. J. Psychiatr Res. 137, 147–157 (2021).
Rao, J. et al. Fecal microbiota transplantation ameliorates gut microbiota imbalance and intestinal barrier damage in rats with stress-induced depressive-like behavior. Eur. J. Neurosci. 53, 3598–3611 (2021).
Cammarota, G. et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66, 569–580 (2017).
Chinese Society of Parenteral and Enteral Nutrition. Chinese expert consensus on standardized methodology and clinical application of fecal microbiota transplantation. Chin. J. Dig. Med. Imag. 23, S5–S13 (2020).
Acknowledgements
We would like to acknowledge and thank all the participants in this study and all the members of the team.
Funding
This research was funded by Traditional Chinese Medicine Scientific Research Fund Project (A) (2022ZA150,2025ZL480).
Author information
Authors and Affiliations
Contributions
Linlin Wang, Sijia Zhang, Xujuan Li and Guoqiang Tian designed the study. Linlin Wang, Sijia Zhang and Yiyun Liu completed the experiment and data collection. Linlin Wang, Sijia Zhang and Deqiang Li contributed to data statistics. Linlin Wang and Sijia Zhang wrote the first draft of the manuscript. Xujuan Li and Yufeng Li reviewed and revised the manuscript. All authors read and approved the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
The study adhered to the ethical standards established by the Ethics Committee of Shulan Hospital (Ethics Number: KY2024024), and it was conducted in accordance with the principles of the Declaration of Helsinki. All subjects provided written informed consent prior to participation.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Wang, L., Zhang, S., Liu, Y. et al. A study on the efficacy and safety of fecal microbiota transplantation as an adjunctive therapy for treating depressive episodes. Sci Rep (2026). https://doi.org/10.1038/s41598-026-41801-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-41801-y
